Prof. Qinglei Gao 高庆蕾
Chief Physician, Professor
Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical, targeted, and comprehensive treatment of gynecologic malignancies, particularly ovarian, cervical, and endometrial cancers. Focuses on complex cases involving ascites or abdominal masses. Does not specialize in diagnosing cervical lesions.
Dr. Gao is Director of the Gynecologic Oncology Department at Tongji Hospital and a professor with postdoctoral training in the US. Selected as a national innovation leader and chief scientist for the National 14th Five-Year Plan ovarian cancer project. Performs approximately 800 surgeries annually, with over 70 percent being complex Level IV procedures. Leads national clinical studies and quality control for ovarian cancer treatment.
Professional roles
- Chair, Obstetrics and Gynecology Branch, Hubei Medical Association
- Member and Secretary, Ovarian Cancer Single-Disease Quality Control Professional Committee, National Cancer Center
Name order: in Chinese the family name comes first (Gao Qinglei). Papers usually list the name as Qinglei Gao or Gao Q.
Selected publications
220 papers on PubMed matched by name and affiliation; 100 as first or senior author since 2016. Most recent first- or senior-author papers:
- Lancet Oncol, 2026 (senior author): Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial. PubMed 42843394
- Cancer Innov, 2026 (senior author): Treatment Advances in Gynecologic Cancers: Insights From Recent Clinical Trials. PubMed 42266555
- Sci Transl Med, 2026 (senior author): Genomic instability drives POSTN(+) myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer. PubMed 42202048
- J Ovarian Res, 2026 (senior author): Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial. PubMed 42186031
- Cancer Biol Med, 2026 (senior author): Treatment implications of T cell DNA damage in anti-tumor immunity. PubMed 42163544
- Chin Med J (Engl), 2026 (first author): Guideline for the management pathway and quality control of ovarian cancer diagnosis and treatment in county-level regions of China (2025 Edition). PubMed 41850857
- J Clin Invest, 2026 (senior author): Tumor cell-derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance. PubMed 41734034
- Cancer Imaging, 2026 (senior author): Deep learning prediction model based on multi-modal transvaginal ultrasound scan images for endometrial cancer. PubMed 41764582
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion